Search Results : Diabetes

1155 interactions found:

Sort by: Relevance Number of Pathways Number of Drugs Number of Diseases
Novel Symbols Name 1 Name 2
Pathways 1
Pathways 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TLE5 and EYA2
Name 1
TLE family member 5, transcriptional modulator
Name2
EYA transcriptional coactivator and phosphatase 2
Pathway 1
  • Repression of WNT target genes
Pathway 2
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TLE5 and ASB3
Name 1
TLE family member 5, transcriptional modulator
Name2
ankyrin repeat and SOCS box containing 3
Pathway 1
  • Repression of WNT target genes
Pathway 2
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TLE5 and UBAP2
Name 1
TLE family member 5, transcriptional modulator
Name2
ubiquitin associated protein 2
Pathway 1
  • Repression of WNT target genes
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TLE5 and ZFHX3
Name 1
TLE family member 5, transcriptional modulator
Name2
zinc finger homeobox 3
Pathway 1
  • Repression of WNT target genes
Pathway 2
  • RUNX3 regulates CDKN1A transcription
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TLE5 and ZNF503
Name 1
TLE family member 5, transcriptional modulator
Name2
zinc finger protein 503
Pathway 1
  • Repression of WNT target genes
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
TLE5 and FOXD2
Name 1
TLE family member 5, transcriptional modulator
Name2
forkhead box D2
Pathway 1
  • Repression of WNT target genes
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
FOXA2 and TLE1
Name 1
forkhead box A2
Name2
TLE family member 1, transcriptional corepressor
Pathway 1
  • Regulation of gene expression in beta cells
  • Positive Regulation of CDH1 Gene Transcription
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Developmental Lineage of Pancreatic Acinar Cells
  • Developmental Lineage of Pancreatic Ductal Cells
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
Pathway 2
  • Formation of the beta-catenin:TCF transactivating complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Deactivation of the beta-catenin transactivating complex
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Negative Regulation of CDH1 Gene Transcription
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
ATXN1 and ZHX3
Name 1
ataxin 1
Name2
zinc fingers and homeoboxes 3
Pathway 1
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Novel
Symbols
ATXN1 and VSNL1
Name 1
ataxin 1
Name2
visinin like 1
Pathway 1
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Novel
Symbols
ATXN1 and SLC6A13
Name 1
ataxin 1
Name2
solute carrier family 6 member 13
Pathway 1
Pathway 2
  • SLC-mediated transport of neurotransmitters
  • Reuptake of GABA
Drugs 1
Drugs 2
  • Guvacine
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Novel
Symbols
ATXN1 and SLC25A51
Name 1
ataxin 1
Name2
solute carrier family 25 member 51
Pathway 1
Pathway 2
  • Nicotinate metabolism
Drugs 1
Drugs 2
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Novel
Symbols
MAPK14 and STK39
Name 1
mitogen-activated protein kinase 14
Name2
serine/threonine kinase 39
Pathway 1
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
Pathway 2
Drugs 1
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
Drugs 2
  • Fostamatinib
Diseases 1
Diseases 2
Novel
Novel
Symbols
MAPK14 and MAP2K7
Name 1
mitogen-activated protein kinase 14
Name2
mitogen-activated protein kinase kinase 7
Pathway 1
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
Pathway 2
  • Oxidative Stress Induced Senescence
  • FCERI mediated MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Uptake and function of anthrax toxins
Drugs 1
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
Drugs 2
  • Pimasertib
Diseases 1
Diseases 2
Novel
Novel
Symbols
MAPK14 and DUSP9
Name 1
mitogen-activated protein kinase 14
Name2
dual specificity phosphatase 9
Pathway 1
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
Pathway 2
  • RAF-independent MAPK1/3 activation
  • Negative regulation of MAPK pathway
  • Signaling by MAPK mutants
Drugs 1
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
BBS4 and PCM1
Name 1
Bardet-Biedl syndrome 4
Name2
pericentriolar material 1
Pathway 1
  • BBSome-mediated cargo-targeting to cilium
Pathway 2
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
Drugs 1
Drugs 2
Diseases 1
  • Bardet-Biedl syndrome (BBS)
Diseases 2
Novel
Novel
Symbols
PSMB5 and ABCB5
Name 1
proteasome 20S subunit beta 5
Name2
ATP binding cassette subfamily B member 5
Pathway 1
  • Activation of NF-kappaB in B cells
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • ER-Phagosome pathway
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Separation of Sister Chromatids
  • FCERI mediated NF-kB activation
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Regulation of ornithine decarboxylase (ODC)
  • ABC-family proteins mediated transport
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Hedgehog ligand biogenesis
  • Hh mutants are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • NIK-->noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • Ub-specific processing proteases
  • Assembly of the pre-replicative complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN stability and activity
  • Neddylation
  • Regulation of expression of SLITs and ROBOs
  • Interleukin-1 signaling
  • Negative regulation of NOTCH4 signaling
  • KEAP1-NFE2L2 pathway
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • Degradation of CDH1
  • Somitogenesis
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Proteasome assembly
  • Proteasome assembly
  • Antigen processing: Ub, ATP-independent proteasomal degradation
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)
  • Degradation of CRY and PER proteins
  • Degradation of CRY and PER proteins
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
Pathway 2
  • ABC-family proteins mediated transport
Drugs 1
  • Bortezomib
  • (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE
  • Carfilzomib
Drugs 2
  • Biricodar
  • Dofequidar
Diseases 1
Diseases 2
Novel
Novel
Symbols
CSTF2 and METTL15
Name 1
cleavage stimulation factor subunit 2
Name2
methyltransferase 15, mitochondrial 12S rRNA N4-cytidine
Pathway 1
  • tRNA processing in the nucleus
  • mRNA 3'-end processing
  • Processing of Capped Intron-Containing Pre-mRNA
  • RNA Polymerase II Transcription Termination
  • Processing of Intronless Pre-mRNAs
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
ARF6 and RAB11FIP3
Name 1
ARF GTPase 6
Name2
RAB11 family interacting protein 3
Pathway 1
  • TBC/RABGAPs
  • Clathrin-mediated endocytosis
  • MET receptor recycling
Pathway 2
  • VxPx cargo-targeting to cilium
Drugs 1
  • 5'-Guanosine-Diphosphate-Monothiophosphate
  • Guanosine-5'-Diphosphate
  • Myristic acid
Drugs 2
Diseases 1
Diseases 2
Novel
Novel
Symbols
NFE2L2 and EIF2AK3
Name 1
NFE2 like bZIP transcription factor 2
Name2
eukaryotic translation initiation factor 2 alpha kinase 3
Pathway 1
  • Neddylation
  • Potential therapeutics for SARS
  • Regulation of HMOX1 expression and activity
  • Heme signaling
  • KEAP1-NFE2L2 pathway
  • KEAP1-NFE2L2 pathway
  • Nuclear events mediated by NFE2L2
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • NFE2L2 regulating TCA cycle genes
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
Pathway 2
  • PERK regulates gene expression
  • ALK mutants bind TKIs
  • Signaling by ALK fusions and activated point mutants
  • KEAP1-NFE2L2 pathway
  • Modulation of host responses by IFN-stimulated genes
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • Permanent neonatal diabetes mellitus (PNDM)
  • Wolcott-Rallison syndrome; SED, Wolcott-Rallison type
Novel
Novel
Symbols
DLG4 and PCDH10
Name 1
discs large MAGUK scaffold protein 4
Name2
protocadherin 10
Pathway 1
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
Pathway 2
Drugs 1
  • Guanidine
  • Guanosine-5'-Monophosphate
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TLE5 and EYA2
Name 1
TLE family member 5, transcriptional modulator
Name2
EYA transcriptional coactivator and phosphatase 2
Pathway 1
  • Repression of WNT target genes
Pathway 2
  • Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TLE5 and ASB3
Name 1
TLE family member 5, transcriptional modulator
Name2
ankyrin repeat and SOCS box containing 3
Pathway 1
  • Repression of WNT target genes
Pathway 2
  • Neddylation
  • Antigen processing: Ubiquitination & Proteasome degradation
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TLE5 and UBAP2
Name 1
TLE family member 5, transcriptional modulator
Name2
ubiquitin associated protein 2
Pathway 1
  • Repression of WNT target genes
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TLE5 and ZFHX3
Name 1
TLE family member 5, transcriptional modulator
Name2
zinc finger homeobox 3
Pathway 1
  • Repression of WNT target genes
Pathway 2
  • RUNX3 regulates CDKN1A transcription
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TLE5 and ZNF503
Name 1
TLE family member 5, transcriptional modulator
Name2
zinc finger protein 503
Pathway 1
  • Repression of WNT target genes
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
TLE5 and FOXD2
Name 1
TLE family member 5, transcriptional modulator
Name2
forkhead box D2
Pathway 1
  • Repression of WNT target genes
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
FOXA2 and TLE1
Name 1
forkhead box A2
Name2
TLE family member 1, transcriptional corepressor
Pathway 1
  • Regulation of gene expression in beta cells
  • Positive Regulation of CDH1 Gene Transcription
  • Formation of axial mesoderm
  • Formation of definitive endoderm
  • Developmental Lineage of Pancreatic Acinar Cells
  • Developmental Lineage of Pancreatic Ductal Cells
  • Developmental Lineage of Multipotent Pancreatic Progenitor Cells
Pathway 2
  • Formation of the beta-catenin:TCF transactivating complex
  • NOTCH1 Intracellular Domain Regulates Transcription
  • Deactivation of the beta-catenin transactivating complex
  • Repression of WNT target genes
  • Repression of WNT target genes
  • Negative Regulation of CDH1 Gene Transcription
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
ATXN1 and ZHX3
Name 1
ataxin 1
Name2
zinc fingers and homeoboxes 3
Pathway 1
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Symbols
ATXN1 and VSNL1
Name 1
ataxin 1
Name2
visinin like 1
Pathway 1
Pathway 2
Drugs 1
Drugs 2
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Symbols
ATXN1 and SLC6A13
Name 1
ataxin 1
Name2
solute carrier family 6 member 13
Pathway 1
Pathway 2
  • SLC-mediated transport of neurotransmitters
  • Reuptake of GABA
Drugs 1
Drugs 2
  • Guvacine
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Symbols
ATXN1 and SLC25A51
Name 1
ataxin 1
Name2
solute carrier family 25 member 51
Pathway 1
Pathway 2
  • Nicotinate metabolism
Drugs 1
Drugs 2
Diseases 1
  • Spinocerebellar ataxia (SCA); Machado-Joseph disease (SCA3)
Diseases 2
Novel
Symbols
MAPK14 and STK39
Name 1
mitogen-activated protein kinase 14
Name2
serine/threonine kinase 39
Pathway 1
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
Pathway 2
Drugs 1
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
Drugs 2
  • Fostamatinib
Diseases 1
Diseases 2
Novel
Symbols
MAPK14 and MAP2K7
Name 1
mitogen-activated protein kinase 14
Name2
mitogen-activated protein kinase kinase 7
Pathway 1
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
Pathway 2
  • Oxidative Stress Induced Senescence
  • FCERI mediated MAPK activation
  • JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1
  • Uptake and function of anthrax toxins
Drugs 1
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
Drugs 2
  • Pimasertib
Diseases 1
Diseases 2
Novel
Symbols
MAPK14 and DUSP9
Name 1
mitogen-activated protein kinase 14
Name2
dual specificity phosphatase 9
Pathway 1
  • NOD1/2 Signaling Pathway
  • p38MAPK events
  • p38MAPK events
  • ERK/MAPK targets
  • Activation of PPARGC1A (PGC-1alpha) by phosphorylation
  • Oxidative Stress Induced Senescence
  • ADP signalling through P2Y purinoceptor 1
  • Platelet sensitization by LDL
  • VEGFA-VEGFR2 Pathway
  • activated TAK1 mediates p38 MAPK activation
  • Activation of the AP-1 family of transcription factors
  • KSRP (KHSRP) binds and destabilizes mRNA
  • Myogenesis
  • Myogenesis
  • RHO GTPases Activate NADPH Oxidases
  • Neutrophil degranulation
  • Regulation of TP53 Activity through Phosphorylation
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • CD163 mediating an anti-inflammatory response
  • Regulation of MITF-M-dependent genes involved in pigmentation
Pathway 2
  • RAF-independent MAPK1/3 activation
  • Negative regulation of MAPK pathway
  • Signaling by MAPK mutants
Drugs 1
  • Minocycline
  • Dasatinib
  • 4-[5-[2-(1-phenyl-ethylamino)-pyrimidin-4-yl]-1-methyl-4-(3-trifluoromethylphenyl)-1H-imidazol-2-yl]-piperidine
  • N-[(3Z)-5-Tert-butyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-ylidene]-N'-(4-chlorophenyl)urea
  • 1-(2,6-Dichlorophenyl)-5-(2,4-Difluorophenyl)-7-Piperidin-4-Yl-3,4-Dihydroquinolin-2(1h)-One
  • Inhibitor of P38 Kinase
  • 6((S)-3-Benzylpiperazin-1-Yl)-3-(Naphthalen-2-Yl)-4-(Pyridin-4-Yl)Pyrazine
  • 3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine
  • 1-(5-Tert-Butyl-2-Methyl-2h-Pyrazol-3-Yl)-3-(4-Chloro-Phenyl)-Urea
  • 3-(Benzyloxy)Pyridin-2-Amine
  • l)-7-Piperazin-1-Yl-3,4-Dihydroquinazolin-2(1h)-One
  • 4-[3-Methylsulfanylanilino]-6,7-Dimethoxyquinazoline
  • Doramapimod
  • 2-Chlorophenol
  • 4-(Fluorophenyl)-1-Cyclopropylmethyl-5-(2-Amino-4-Pyrimidinyl)Imidazole
  • SB220025
  • 4-(2-HYDROXYBENZYLAMINO)-N-(3-(4-FLUOROPHENOXY)PHENYL)PIPERIDINE-1-SULFONAMIDE
  • Triazolopyridine
  • KC706
  • Talmapimod
  • VX-702
  • R-1487
  • 1-[1-(3-aminophenyl)-3-tert-butyl-1H-pyrazol-5-yl]-3-naphthalen-1-ylurea
  • N-ethyl-4-{[5-(methoxycarbamoyl)-2-methylphenyl]amino}-5-methylpyrrolo[2,1-f][1,2,4]triazine-6-carboxamide
  • N-[2-methyl-5-(methylcarbamoyl)phenyl]-2-{[(1R)-1-methylpropyl]amino}-1,3-thiazole-5-carboxamide
  • Neflamapimod
  • N-cyclopropyl-4-methyl-3-[1-(2-methylphenyl)phthalazin-6-yl]benzamide
  • 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE
  • 4-[5-(3-IODO-PHENYL)-2-(4-METHANESULFINYL-PHENYL)-1H-IMIDAZOL-4-YL]-PYRIDINE
  • N-cyclopropyl-2',6-dimethyl-4'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-3-carboxamide
  • 4-[3-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL]PYRIDINE
  • 4-{4-[(5-hydroxy-2-methylphenyl)amino]quinolin-7-yl}-1,3-thiazole-2-carbaldehyde
  • N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)-4-biphenylcarboxamide
  • N-(cyclopropylmethyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide
  • N~3~-cyclopropyl-N~4~'-(cyclopropylmethyl)-6-methylbiphenyl-3,4'-dicarboxamide
  • PH-797804
  • 2-fluoro-4-[4-(4-fluorophenyl)-1H-pyrazol-3-yl]pyridine
  • SD-0006
  • N-(3-TERT-BUTYL-1H-PYRAZOL-5-YL)-N'-{4-CHLORO-3-[(PYRIDIN-3-YLOXY)METHYL]PHENYL}UREA
  • N-[4-CHLORO-3-(PYRIDIN-3-YLOXYMETHYL)-PHENYL]-3-FLUORO-
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[3-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-5-YL]BENZAMIDE
  • 3-fluoro-N-1H-indol-5-yl-5-morpholin-4-ylbenzamide
  • 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE
  • 3-(2-CHLOROPHENYL)-1-(2-{[(1S)-2-HYDROXY-1,2-DIMETHYLPROPYL]AMINO}PYRIMIDIN-4-YL)-1-(4-METHOXYPHENYL)UREA
  • 8-(2-CHLOROPHENYLAMINO)-2-(2,6-DIFLUOROPHENYLAMINO)-9-ETHYL-9H-PURINE-1,7-DIIUM
  • 2-(2,6-DIFLUOROPHENOXY)-N-(2-FLUOROPHENYL)-9-ISOPROPYL-9H-PURIN-8-AMINE
  • N,4-dimethyl-3-[(1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)amino]benzamide
  • N-cyclopropyl-3-{[1-(2,4-difluorophenyl)-7-methyl-6-oxo-6,7-dihydro-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-4-methylbenzamide
  • N-cyclopropyl-4-methyl-3-{2-[(2-morpholin-4-ylethyl)amino]quinazolin-6-yl}benzamide
  • 6-[4-(2-fluorophenyl)-1,3-oxazol-5-yl]-N-(1-methylethyl)-1,3-benzothiazol-2-amine
  • 2-(ETHOXYMETHYL)-4-(4-FLUOROPHENYL)-3-[2-(2-HYDROXYPHENOXY)PYRIMIDIN-4-YL]ISOXAZOL-5(2H)-ONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL][3-(PIPERIDIN-4-YLOXY)PHENYL]METHANONE
  • [5-AMINO-1-(4-FLUOROPHENYL)-1H-PYRAZOL-4-YL](3-{[(2R)-2,3-DIHYDROXYPROPYL]OXY}PHENYL)METHANONE
  • 4-[4-(4-Fluorophenyl)-2-[4-[(R)-methylsulfinyl]phenyl]-1H-imidazol-5-yl]pyridine
  • 4-(4-FLUOROPHENYL)-1-CYCLOROPROPYLMETHYL-5-(4-PYRIDYL)-IMIDAZOLE
  • 3-FLUORO-5-MORPHOLIN-4-YL-N-[1-(2-PYRIDIN-4-YLETHYL)-1H-INDOL-6-YL]BENZAMIDE
  • Fostamatinib
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
BBS4 and PCM1
Name 1
Bardet-Biedl syndrome 4
Name2
pericentriolar material 1
Pathway 1
  • BBSome-mediated cargo-targeting to cilium
Pathway 2
  • Regulation of PLK1 Activity at G2/M Transition
  • Loss of Nlp from mitotic centrosomes
  • Recruitment of mitotic centrosome proteins and complexes
  • Loss of proteins required for interphase microtubule organization from the centrosome
  • Recruitment of NuMA to mitotic centrosomes
  • Anchoring of the basal body to the plasma membrane
  • AURKA Activation by TPX2
Drugs 1
Drugs 2
Diseases 1
  • Bardet-Biedl syndrome (BBS)
Diseases 2
Novel
Symbols
PSMB5 and ABCB5
Name 1
proteasome 20S subunit beta 5
Name2
ATP binding cassette subfamily B member 5
Pathway 1
  • Activation of NF-kappaB in B cells
  • Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha
  • ER-Phagosome pathway
  • Cross-presentation of soluble exogenous antigens (endosomes)
  • Autodegradation of Cdh1 by Cdh1:APC/C
  • SCF-beta-TrCP mediated degradation of Emi1
  • APC/C:Cdc20 mediated degradation of Securin
  • APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1
  • Cdc20:Phospho-APC/C mediated degradation of Cyclin A
  • Vpu mediated degradation of CD4
  • Vif-mediated degradation of APOBEC3G
  • SCF(Skp2)-mediated degradation of p27/p21
  • Degradation of beta-catenin by the destruction complex
  • Downstream TCR signaling
  • Regulation of activated PAK-2p34 by proteasome mediated degradation
  • Separation of Sister Chromatids
  • FCERI mediated NF-kB activation
  • Autodegradation of the E3 ubiquitin ligase COP1
  • Regulation of ornithine decarboxylase (ODC)
  • ABC-family proteins mediated transport
  • AUF1 (hnRNP D0) binds and destabilizes mRNA
  • Asymmetric localization of PCP proteins
  • Degradation of AXIN
  • Degradation of DVL
  • Hedgehog ligand biogenesis
  • Hh mutants are degraded by ERAD
  • Dectin-1 mediated noncanonical NF-kB signaling
  • CLEC7A (Dectin-1) signaling
  • Degradation of GLI1 by the proteasome
  • Degradation of GLI2 by the proteasome
  • GLI3 is processed to GLI3R by the proteasome
  • Hedgehog 'on' state
  • Regulation of RAS by GAPs
  • TNFR2 non-canonical NF-kB pathway
  • NIK-->noncanonical NF-kB signaling
  • Defective CFTR causes cystic fibrosis
  • MAPK6/MAPK4 signaling
  • UCH proteinases
  • Ub-specific processing proteases
  • Assembly of the pre-replicative complex
  • Orc1 removal from chromatin
  • CDK-mediated phosphorylation and removal of Cdc6
  • G2/M Checkpoints
  • Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A
  • Ubiquitin-dependent degradation of Cyclin D
  • The role of GTSE1 in G2/M progression after G2 checkpoint
  • FBXL7 down-regulates AURKA during mitotic entry and in early mitosis
  • RUNX1 regulates transcription of genes involved in differentiation of HSCs
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX2 expression and activity
  • Regulation of RUNX3 expression and activity
  • Regulation of PTEN stability and activity
  • Neddylation
  • Regulation of expression of SLITs and ROBOs
  • Interleukin-1 signaling
  • Negative regulation of NOTCH4 signaling
  • KEAP1-NFE2L2 pathway
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • Degradation of CDH1
  • Somitogenesis
  • Antigen processing: Ubiquitination & Proteasome degradation
  • Proteasome assembly
  • Proteasome assembly
  • Antigen processing: Ub, ATP-independent proteasomal degradation
  • GSK3B-mediated proteasomal degradation of PD-L1(CD274)
  • SPOP-mediated proteasomal degradation of PD-L1(CD274)
  • AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274)
  • Degradation of CRY and PER proteins
  • Degradation of CRY and PER proteins
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
  • Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide
Pathway 2
  • ABC-family proteins mediated transport
Drugs 1
  • Bortezomib
  • (3AR,6R,6AS)-6-((S)-((S)-CYCLOHEX-2-ENYL)(HYDROXY)METHYL)-6A-METHYL-4-OXO-HEXAHYDRO-2H-FURO[3,2-C]PYRROLE-6-CARBALDEHYDE
  • Carfilzomib
Drugs 2
  • Biricodar
  • Dofequidar
Diseases 1
Diseases 2
Novel
Symbols
CSTF2 and METTL15
Name 1
cleavage stimulation factor subunit 2
Name2
methyltransferase 15, mitochondrial 12S rRNA N4-cytidine
Pathway 1
  • tRNA processing in the nucleus
  • mRNA 3'-end processing
  • Processing of Capped Intron-Containing Pre-mRNA
  • RNA Polymerase II Transcription Termination
  • Processing of Intronless Pre-mRNAs
Pathway 2
Drugs 1
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
ARF6 and RAB11FIP3
Name 1
ARF GTPase 6
Name2
RAB11 family interacting protein 3
Pathway 1
  • TBC/RABGAPs
  • Clathrin-mediated endocytosis
  • MET receptor recycling
Pathway 2
  • VxPx cargo-targeting to cilium
Drugs 1
  • 5'-Guanosine-Diphosphate-Monothiophosphate
  • Guanosine-5'-Diphosphate
  • Myristic acid
Drugs 2
Diseases 1
Diseases 2
Novel
Symbols
NFE2L2 and EIF2AK3
Name 1
NFE2 like bZIP transcription factor 2
Name2
eukaryotic translation initiation factor 2 alpha kinase 3
Pathway 1
  • Neddylation
  • Potential therapeutics for SARS
  • Regulation of HMOX1 expression and activity
  • Heme signaling
  • KEAP1-NFE2L2 pathway
  • KEAP1-NFE2L2 pathway
  • Nuclear events mediated by NFE2L2
  • GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2
  • NFE2L2 regulating TCA cycle genes
  • NFE2L2 regulating inflammation associated genes
  • NFE2L2 regulating anti-oxidant/detoxification enzymes
  • NFE2L2 regulates pentose phosphate pathway genes
  • NFE2L2 regulating tumorigenic genes
  • NFE2L2 regulating MDR associated enzymes
  • NFE2L2 regulating ER-stress associated genes
  • Regulation of NFE2L2 gene expression
  • Regulation of NFE2L2 gene expression
  • Regulation of PD-L1(CD274) transcription
Pathway 2
  • PERK regulates gene expression
  • ALK mutants bind TKIs
  • Signaling by ALK fusions and activated point mutants
  • KEAP1-NFE2L2 pathway
  • Modulation of host responses by IFN-stimulated genes
Drugs 1
Drugs 2
Diseases 1
Diseases 2
  • Permanent neonatal diabetes mellitus (PNDM)
  • Wolcott-Rallison syndrome; SED, Wolcott-Rallison type
Novel
Symbols
DLG4 and PCDH10
Name 1
discs large MAGUK scaffold protein 4
Name2
protocadherin 10
Pathway 1
  • Signaling by ERBB4
  • Trafficking of AMPA receptors
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Unblocking of NMDA receptors, glutamate binding and activation
  • Ras activation upon Ca2+ influx through NMDA receptor
  • NrCAM interactions
  • Activation of Ca-permeable Kainate Receptor
  • RHO GTPases activate CIT
  • RAF/MAP kinase cascade
  • LGI-ADAM interactions
  • Neurexins and neuroligins
  • Neurexins and neuroligins
  • Synaptic adhesion-like molecules
  • Assembly and cell surface presentation of NMDA receptors
  • Negative regulation of NMDA receptor-mediated neuronal transmission
  • Long-term potentiation
Pathway 2
Drugs 1
  • Guanidine
  • Guanosine-5'-Monophosphate
Drugs 2
Diseases 1
Diseases 2

Page 35 out of 58 pages

© Madhavi K. Ganapathiraju 2012-2025